Evidence map›Paper›PMID 33222343›Full record

GuidelineNephrology (Carlton, Vic.)2021

Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors.

Desmond Y H Yap, Lawrence P McMahon, Chuan-Ming Hao, Nan Hu, Hirokazu Okada, Yusuke Suzuki, Sung Gyun Kim, Soo Kun Lim, Kriengsak Vareesangthip, Chi-Chih Hung and 2 more

Registry-linked trialOpen access · bronzeAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Nephrology (Carlton, Vic.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06903559 (Effect of Roxadustat on Cardiovascular System and Malnutrition-Inflammation-Atherosclerosis), which is not on this map. Cited by 61 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 5 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06903559 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of Roxadustat on Cardiovascular System and Malnutrition-Inflammation-Atherosclerosis (MIA) Syndrome in Hemodialysis Patients: A Randomized Controlled Study

TypeinterventionalSponsorMansoura UniversityRan2025 to 2025Enrolled46ConditionsKidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease, Cardiovascular Diseases (CVD)ArmsRoxadustat, Conventional Anemia Management
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 5 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Trial
  7. Trial
  8. Review
  9. Observational
  10. Observational
  11. Navigating Anemia Therapy in CKD With Hypoxia-Inducible Factor Activators: A Review.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Observational
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 8 countries.

Desmond Y H YapDivision of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Hong Kong.ORCID https://orcid.org/0000-0001-8179-8293
Lawrence P McMahonDepartment of Renal and Obstetric Medicine, Eastern Health Clinical School, Monash University, Melbourne, Australia.
Chuan-Ming HaoDivison of Nephrology, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Nan HuRenal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Beijing, P. R. China.
Hirokazu OkadaDepartment of Nephrology, Saitama Medical University, Irumagun, Saitama, Japan.
Yusuke SuzukiDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Sung Gyun KimDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Seoul, South Korea.
Soo Kun LimDivision of Nephrology, Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia.ORCID https://orcid.org/0000-0001-7589-5150
Kriengsak VareesangthipDivision of Nephrology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chi-Chih HungDivision of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
APSN HIF-PHI Recommendation Committee
Eastern Health · AUFudan University · CNHallym University Kangnam Sacred Heart Hospital · KRJuntendo University · JPKaohsiung Medical University · TWPeking University · CNQueen Mary Hospital · CNSaitama Medical University · JPSiriraj Hospital · THThe University of Tokyo · JPUniversity Malaya Medical Centre · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal anaemia is a common and important complication in patients with chronic kidney disease (CKD). The current standard-of-care treatment for renal anaemia in CKD patients involves ensuring adequate iron stores and administration of erythropoietin stimulating agents (ESA). Hypoxia inducible factor (HIF) is a key transcription factor primarily involved in the cellular regulation and efficiency of oxygen delivery. Manipulation of the HIF pathway by the use of HIF-prolyl hydroxylase inhibitors (HIF-PHI) has emerged as a novel approach for renal anaemia management. Despite it being approved for clinical use in various Asia-Pacific countries, its novelty mandates the need for nephrologists and clinicians generally in the region to well understand potential benefits and harms when prescribing this class of drug. The Asian Pacific society of nephrology HIF-PHI Recommendation Committee, formed by a panel of 11 nephrologists from the Asia-Pacific region who have clinical experience or have been investigators in HIF-PHI studies, reviewed and deliberated on the clinical and preclinical data concerning HIF-PHI. This recommendation summarizes the consensus views of the committee regarding the use of HIF-PHI, taking into account both available data and expert opinion in areas where evidence remains scarce.

Indexed as

AnemiaConsensusHumansHypoxia-Inducible Factor-Proline DioxygenasesNephrologyPatient SafetyProlyl-Hydroxylase InhibitorsRenal Insufficiency, ChronicRisk AssessmentRisk FactorsTreatment OutcomeHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsanaemiaAsian Pacificchronic kidney diseasehypoxia inducible factorprolyl hydroxylase inhibitor

Identifiers

PMID33222343
PMCPMC7898910
OpenAlexW3108166106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.